Digitales Bildkuratieren als Bereicherung des Museumsbesuchs

Das von der Deutschen Forschungsgemeinschaft (DFG) geförderte Forschungsprojekt Curating Digital Images: Ethnographic Perspectives on the Affordances of Digital Images in Museum and Heritage Contexts hat sich im Rahmen des Schwerpunktprogramms Das Digitale Bild mit diesen und anderen Fragen beschäftigt. Die Forscher:innen der Universität Tübingen und der Humboldt-Universität zu Berlin möchten mit dieser Handreichung einen Beitrag zur Debatte rund um digitale Bildtechnologien im Museums- und Kunstsektor leisten. Das Projekt umfasst zwei Arbeitsbereiche, die sich diesem Thema aus unterschiedlichen Richtungen annähern

Wearable Pressure Sensing for Vojta Therapy Guidance

The authors propose a glove with pressure sensitive fingertips and muscle tension detection of the thumb to aid in the physiotherapy of infants, children and adults according to Vojta. The therapy has to be carried out at home by the parents of children with cerebral palsy, or other movement disturbances up to 4 times per day. Often, parents struggle to carry out the practices because of insecurities regarding the therapy’s proper application. The presented glove is tailored towards the specific needs of Vojta therapy, e.g. flexibility and small sensor size, and can help parents gather objective data on their therapy application at home. It has been tested in multiple therapy sessions on adult probands and seems to be a suitable tool to support parents and therapists in training alike. Additionally, the results of the accompanied therapy sessions provide arguments against what the critics have often cited about the painfulness of the therapy

Distinct and Non-Redundant Roles of Microglia and Myeloid Subsets in Mouse Models of Alzheimer's Disease

peer reviewedMononuclear phagocytes are important modulators of Alzheimer's disease (AD), but the specific functions of resident microglia, bone marrow-derived mononuclear cells, and perivascular macrophages have not been resolved. To elucidate the spatiotemporal roles of mononuclear phagocytes during disease, we targeted myeloid cell subsets from different compartments and examined disease pathogenesis in three different mouse models of AD (APP(swe/PS1), APP(swe), and APP23 mice). We identified chemokine receptor 2 (CCR2)-expressing myeloid cells as the population that was preferentially recruited to β-amyloid (Aβ) deposits. Unexpectedly, AD brains with dysfunctional microglia and devoid of parenchymal bone marrow-derived phagocytes did not show overt changes in plaque pathology and Aβ load. In contrast, restriction of CCR2 deficiency to perivascular myeloid cells drastically impaired β-amyloid clearance and amplified vascular Aβ deposition, while parenchymal plaque deposition remained unaffected. Together, our data advocate selective functions of CCR2-expressing myeloid subsets, which could be targeted specifically to modify disease burden in AD

Actively personalized vaccination trial for newly diagnosed glioblastoma

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential3. There is limited intratumoural infiltration of immune cells4 in glioblastoma and these tumours contain only 30–50 non-synonymous mutations5. Exploitation of the full repertoire of tumour antigens—that is, both unmutated antigens and neoepitopes—may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-l-lysine carboxymethylcellulose) and granulocyte–macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8+ T cells. APVAC2 induced predominantly CD4+ T cell responses of T helper 1 type against predicted neoepitopes.</p